Report Detail
Global Peptide Based Metabolic Disorders Therapeutics Market Size, Status and Forecast 2019-2025
- RnM3378251 |
- 16 July, 2019 |
- Global |
- 98 Pages |
- QYResearch |
- Other
A metabolic disorder can happen when abnormal chemical reactions in the body alter the normal metabolic process. It can also be defined as inherited single gene anomaly, most of which are autosomal recessive. Peptide therapeutics are used to treat metabolic disorders owing to their stability, efficiency, safety as well as tolerability.
North America is expected to dominate the global market in terms of higher market share.
The liraglutide segment by drug class reflects a higher market share by revenue and dominates the global market by drug class.
In 2018, the global Peptide Based Metabolic Disorders Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Peptide Based Metabolic Disorders Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Peptide Based Metabolic Disorders Therapeutics development in United States, Europe and China.
The key players covered in this study
AstraZeneca
Ingro Finanz (Bachem)
Eli Lilly
Ipsen
Merck
Novo Nordisk
PolyPeptide Group
Teva Pharmaceutical
Market segment by Type, the product can be split into
Exenatide
Liraglutide
Others
Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Peptide Based Metabolic Disorders Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Peptide Based Metabolic Disorders Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Peptide Based Metabolic Disorders Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered
- 1.4 Market Analysis by Type
- 1.4.1 Global Peptide Based Metabolic Disorders Therapeutics Market Size Growth Rate by Type (2014-2025)
- 1.4.2 Exenatide
- 1.4.3 Liraglutide
- 1.4.4 Others
- 1.5 Market by Application
- 1.5.1 Global Peptide Based Metabolic Disorders Therapeutics Market Share by Application (2014-2025)
- 1.5.2 Hospital Pharmacies
- 1.5.3 Retail Pharmacies
- 1.5.4 Online Pharmacies
- 1.6 Study Objectives
- 1.7 Years Considered
2 Global Growth Trends
- 2.1 Peptide Based Metabolic Disorders Therapeutics Market Size
- 2.2 Peptide Based Metabolic Disorders Therapeutics Growth Trends by Regions
- 2.2.1 Peptide Based Metabolic Disorders Therapeutics Market Size by Regions (2014-2025)
- 2.2.2 Peptide Based Metabolic Disorders Therapeutics Market Share by Regions (2014-2019)
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
- 2.3.3 Market Opportunities
3 Market Share by Key Players
- 3.1 Peptide Based Metabolic Disorders Therapeutics Market Size by Manufacturers
- 3.1.1 Global Peptide Based Metabolic Disorders Therapeutics Revenue by Manufacturers (2014-2019)
- 3.1.2 Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share by Manufacturers (2014-2019)
- 3.1.3 Global Peptide Based Metabolic Disorders Therapeutics Market Concentration Ratio (CR5 and HHI)
- 3.2 Peptide Based Metabolic Disorders Therapeutics Key Players Head office and Area Served
- 3.3 Key Players Peptide Based Metabolic Disorders Therapeutics Product/Solution/Service
- 3.4 Date of Enter into Peptide Based Metabolic Disorders Therapeutics Market
- 3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
- 4.1 Global Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2014-2019)
- 4.2 Global Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2014-2019)
5 United States
- 5.1 United States Peptide Based Metabolic Disorders Therapeutics Market Size (2014-2019)
- 5.2 Peptide Based Metabolic Disorders Therapeutics Key Players in United States
- 5.3 United States Peptide Based Metabolic Disorders Therapeutics Market Size by Type
- 5.4 United States Peptide Based Metabolic Disorders Therapeutics Market Size by Application
6 Europe
- 6.1 Europe Peptide Based Metabolic Disorders Therapeutics Market Size (2014-2019)
- 6.2 Peptide Based Metabolic Disorders Therapeutics Key Players in Europe
- 6.3 Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Type
- 6.4 Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Application
7 China
- 7.1 China Peptide Based Metabolic Disorders Therapeutics Market Size (2014-2019)
- 7.2 Peptide Based Metabolic Disorders Therapeutics Key Players in China
- 7.3 China Peptide Based Metabolic Disorders Therapeutics Market Size by Type
- 7.4 China Peptide Based Metabolic Disorders Therapeutics Market Size by Application
8 Japan
- 8.1 Japan Peptide Based Metabolic Disorders Therapeutics Market Size (2014-2019)
- 8.2 Peptide Based Metabolic Disorders Therapeutics Key Players in Japan
- 8.3 Japan Peptide Based Metabolic Disorders Therapeutics Market Size by Type
- 8.4 Japan Peptide Based Metabolic Disorders Therapeutics Market Size by Application
9 Southeast Asia
- 9.1 Southeast Asia Peptide Based Metabolic Disorders Therapeutics Market Size (2014-2019)
- 9.2 Peptide Based Metabolic Disorders Therapeutics Key Players in Southeast Asia
- 9.3 Southeast Asia Peptide Based Metabolic Disorders Therapeutics Market Size by Type
- 9.4 Southeast Asia Peptide Based Metabolic Disorders Therapeutics Market Size by Application
10 India
- 10.1 India Peptide Based Metabolic Disorders Therapeutics Market Size (2014-2019)
- 10.2 Peptide Based Metabolic Disorders Therapeutics Key Players in India
- 10.3 India Peptide Based Metabolic Disorders Therapeutics Market Size by Type
- 10.4 India Peptide Based Metabolic Disorders Therapeutics Market Size by Application
11 Central & South America
- 11.1 Central & South America Peptide Based Metabolic Disorders Therapeutics Market Size (2014-2019)
- 11.2 Peptide Based Metabolic Disorders Therapeutics Key Players in Central & South America
- 11.3 Central & South America Peptide Based Metabolic Disorders Therapeutics Market Size by Type
- 11.4 Central & South America Peptide Based Metabolic Disorders Therapeutics Market Size by Application
12 International Players Profiles
- 12.1 AstraZeneca
- 12.1.1 AstraZeneca Company Details
- 12.1.2 Company Description and Business Overview
- 12.1.3 Peptide Based Metabolic Disorders Therapeutics Introduction
- 12.1.4 AstraZeneca Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2014-2019)
- 12.1.5 AstraZeneca Recent Development
- 12.2 Ingro Finanz (Bachem)
- 12.2.1 Ingro Finanz (Bachem) Company Details
- 12.2.2 Company Description and Business Overview
- 12.2.3 Peptide Based Metabolic Disorders Therapeutics Introduction
- 12.2.4 Ingro Finanz (Bachem) Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2014-2019)
- 12.2.5 Ingro Finanz (Bachem) Recent Development
- 12.3 Eli Lilly
- 12.3.1 Eli Lilly Company Details
- 12.3.2 Company Description and Business Overview
- 12.3.3 Peptide Based Metabolic Disorders Therapeutics Introduction
- 12.3.4 Eli Lilly Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2014-2019)
- 12.3.5 Eli Lilly Recent Development
- 12.4 Ipsen
- 12.4.1 Ipsen Company Details
- 12.4.2 Company Description and Business Overview
- 12.4.3 Peptide Based Metabolic Disorders Therapeutics Introduction
- 12.4.4 Ipsen Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2014-2019)
- 12.4.5 Ipsen Recent Development
- 12.5 Merck
- 12.5.1 Merck Company Details
- 12.5.2 Company Description and Business Overview
- 12.5.3 Peptide Based Metabolic Disorders Therapeutics Introduction
- 12.5.4 Merck Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2014-2019)
- 12.5.5 Merck Recent Development
- 12.6 Novo Nordisk
- 12.6.1 Novo Nordisk Company Details
- 12.6.2 Company Description and Business Overview
- 12.6.3 Peptide Based Metabolic Disorders Therapeutics Introduction
- 12.6.4 Novo Nordisk Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2014-2019)
- 12.6.5 Novo Nordisk Recent Development
- 12.7 PolyPeptide Group
- 12.7.1 PolyPeptide Group Company Details
- 12.7.2 Company Description and Business Overview
- 12.7.3 Peptide Based Metabolic Disorders Therapeutics Introduction
- 12.7.4 PolyPeptide Group Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2014-2019)
- 12.7.5 PolyPeptide Group Recent Development
- 12.8 Teva Pharmaceutical
- 12.8.1 Teva Pharmaceutical Company Details
- 12.8.2 Company Description and Business Overview
- 12.8.3 Peptide Based Metabolic Disorders Therapeutics Introduction
- 12.8.4 Teva Pharmaceutical Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2014-2019)
- 12.8.5 Teva Pharmaceutical Recent Development
13 Market Forecast 2019-2025
- 13.1 Market Size Forecast by Regions
- 13.2 United States
- 13.3 Europe
- 13.4 China
- 13.5 Japan
- 13.6 Southeast Asia
- 13.7 India
- 13.8 Central & South America
- 13.9 Market Size Forecast by Product (2019-2025)
- 13.10 Market Size Forecast by Application (2019-2025)
14 Analyst's Viewpoints/Conclusions
15 Appendix
- 15.1 Research Methodology
- 15.1.1 Methodology/Research Approach
- 15.1.1.1 Research Programs/Design
- 15.1.1.2 Market Size Estimation
- 12.1.1.3 Market Breakdown and Data Triangulation
- 15.1.2 Data Source
- 15.1.2.1 Secondary Sources
- 15.1.2.2 Primary Sources
- 15.1.1 Methodology/Research Approach
- 15.2 Disclaimer
Summary:
Get latest Market Research Reports on Global Peptide Based Metabolic Disorders Therapeutics . Industry analysis & Market Report on Global Peptide Based Metabolic Disorders Therapeutics is a syndicated market report, published as Global Peptide Based Metabolic Disorders Therapeutics Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Global Peptide Based Metabolic Disorders Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
